Hepatic bile acid accretion correlates with cholestatic liver injury and therapeutic response in Cyp2c70 knockout mice with a humanized bile acid composition.

Cyp2c70 knockout (KO) mice lack the liver enzyme responsible for synthesis of 6-hydroxylated muricholate bile acid species and possess a more hydrophobic human-like bile acid composition. Cyp2c70 KO mice develop cholestatic liver injury that can be prevented by administration of an ileal bile acid transporter (IBAT) inhibitor. In this study, we investigated the potential of an ileal bile acid transporter (IBAT) inhibitor (SC-435) and steroidal FXR agonist (cilofexor) to modulate established hepatobiliary injury and the consequent relationship of intrahepatic bile acid content and hydrophobicity to the cholestatic liver injury phenotype. Oral administration of SC-435, cilofexor, or combined treatment for 2 weeks markedly reduced serum markers of liver injury and improved histological and gene expression markers of fibrosis, liver inflammation, and ductular reaction in male and female Cyp2c70 KO mice, with greatest benefit in the combination treatment group. The IBAT inhibitor and FXR agonist significantly reduced intrahepatic bile acid content but not hepatic bile acid pool hydrophobicity, and markers of liver injury were strongly correlated with intrahepatic total bile acid and taurochenodeoxycholic acid accretion. Biomarkers of liver injury increased linearly with similar hepatic thresholds for pathological accretion of hydrophobic bile acids in male and female Cyp2c70 KO mice. These findings further support targeting intrahepatic bile acid retention as a component of treatments for cholestatic liver disease.

• Publication year

  2024

• Venue

  American Journal of Physiology - Gastrointestinal and Liver Physiology

• Publication date

  2024-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1152/ajpgi.00129.2024PMID 39350733PMCID PMC11684888
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The underappreciated diversity of bile acid modifications.

  2024cited by this paper
• Quantifying Forms and Functions of Enterohepatic Bile Acid Pools in Mice

  2024cited by this paper
• Primary Biliary Cholangitis: Pathophysiology.

  2023cited by this paper
• Combined, elobixibat, and colestyramine reduced cholesterol toxicity in a mouse model of metabolic dysfunction-associated steatotic liver disease

  2023cited by this paper
• Combined inhibition of bile salt synthesis and intestinal uptake reduces cholestatic liver damage and colonic bile salts in mice

  2023cited by this paper
• Bile Acid Sequestration via Colesevelam Reduces Bile Acid Hydrophobicity and Improves Liver Pathology in Cyp2c70−/− Mice with a Human-like Bile Acid Composition

  2023cited by this paper
• Hepatic farnesoid X receptor is necessary to facilitate ductular reaction and expression of heme biosynthetic genes

  2023cited by this paper
• Inhibiting Wnt Signaling Reduces Cholestatic Injury by Disrupting the Inflammatory Axis

  2023cited by this paper
• Non-steroidal FXR agonist cilofexor improves cholestatic liver injury in the Mdr2-/- mouse model of sclerosing cholangitis

  2023cited by this paper
• Combining ASBT inhibitor and FGF15 treatments enhances therapeutic efficacy against cholangiopathy in female but not male Cyp2c70 KO mice

  2023cited by this paper
• Glycine-β-Muricholic Acid Improves Liver Fibrosis and Gut Barrier Function by Reducing Bile Acid Pool Size and Hydrophobicity in Male Cyp2c70 Knockout Mice

  2023cited by this paper
• Gut microbiota depletion aggravates bile acid-induced liver pathology in mice with a human-like bile acid composition

  2023cited by this paper
• Sex-, age-, and organ-dependent improvement of bile acid hydrophobicity by ursodeoxycholic acid treatment: A study using a mouse model with human-like bile acid composition

  2022cited by this paper
• Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.

  2022cited by this paper
• Farnesoid X receptor antagonizes macrophage-dependent licensing of effector T lymphocytes and progression of sclerosing cholangitis

  2022cited by this paper
• Pathophysiological Roles of Ductular Reaction in Liver Inflammation and Hepatic Fibrogenesis

  2022cited by this paper
• Primary biliary cholangitis as a roadmap for the development of novel treatments of cholestatic liver diseases.

  2022cited by this paper
• Perinatal exposure to UDCA prevents neonatal cholestasis in Cyp2c70-/- mice with human-like bile acids

  2022cited by this paper
• Systemic ASBT inactivation protects against liver damage in obstructive cholestasis in mice

  2022cited by this paper
• Ileal bile acid transporter inhibition in Cyp2c70 KO mice ameliorates cholestatic liver injury

  2022cited by this paper
• Safety and sustained efficacy of the farnesoid X receptor (FXR) agonist cilofexor over a 96-week open-label extension in patients with PSC.

  2022cited by this paper
• Short-term obeticholic acid treatment does not impact cholangiopathy in Cyp2c70-deficient mice with a human-like bile acid composition.

  2022cited by this paper
• Active enterohepatic cycling is not required for the choleretic actions of 24-norUrsodeoxycholic acid in mice

  2021cited by this paper
• Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study.

  2021cited by this paper
• Novel therapeutic targets for cholestatic and fatty liver disease

  2021cited by this paper
• Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: Phase 2 study.

  2021cited by this paper
• The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model

  2021cited by this paper
• Cholangiopathy and Biliary Fibrosis in Cyp2c70-Deficient Mice Are Fully Reversed by Ursodeoxycholic Acid

  2020cited by this paper
• Of mice and men: murine bile acids explain species differences in the regulation of bile acid and cholesterol metabolism[S]

  2020cited by this paper
• The role of bile acids in cholestatic liver injury

  2020cited by this paper
• Hepatic NFAT signaling regulates the expression of inflammatory cytokines in cholestasis

  2020cited by this paper
• Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis.

  2020cited by this paper
• Nonsteroidal FXR Ligands: Current Status and Clinical Applications.

  2019cited by this paper
• Animal models to study bile acid metabolism.

  2019cited by this paper
• The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS‐9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis

  2019cited by this paper
• Cholangiocyte pathobiology

  2019cited by this paper
• UDCA, NorUDCA, and TUDCA in Liver Diseases: A Review of Their Mechanisms of Action and Clinical Applications.

  2019cited by this paper
• A human-like bile acid pool induced by deletion of hepatic Cyp2c70 modulates effects of FXR activation in mice[S]

  2019cited by this paper
• Colesevelam attenuates cholestatic liver and bile duct injury in Mdr2−/− mice by modulating composition, signalling and excretion of faecal bile acids

  2018cited by this paper
• Na+‐taurocholate cotransporting polypeptide inhibition has hepatoprotective effects in cholestasis in mice

  2018cited by this paper
• Placebo‐Controlled Randomized Trial of an Intestinal Bile Salt Transport Inhibitor for Pruritus in Alagille Syndrome

  2018cited by this paper
• A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis

  2018cited by this paper
• Hepatobiliary transport kinetics of the conjugated bile acid tracer 11C-CSar quantified in healthy humans and patients by positron emission tomography.

  2017cited by this paper
• New therapeutic concepts in bile acid transport and signaling for management of cholestasis

  2017cited by this paper
• The ascending pathophysiology of cholestatic liver disease

  2017cited by this paper
• Bile acids initiate cholestatic liver injury by triggering a hepatocyte-specific inflammatory response.

  2017cited by this paper
• QuPath: Open source software for digital pathology image analysis

  2017cited by this paper
• Biliary bile acids in hepatobiliary injury - What is the link?

  2017cited by this paper
• Primary sclerosing cholangitis - a comprehensive review.

  2017cited by this paper
• Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet–fed mice

  2016cited by this paper
• Pharmacological inhibition of apical sodium‐dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice

  2016cited by this paper
• Clinical Chemistry Reference Intervals for C57BL/6J, C57BL/6N, and C3HeB/FeJ Mice (Mus musculus).

  2016cited by this paper
• Cyp2c70 is responsible for the species difference in bile acid metabolism between mice and humans[S]

  2016cited by this paper
• Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis.

  2016cited by this paper
• Intestinal transport and metabolism of bile acids

  2015cited by this paper
• Discovery of a highly potent, nonabsorbable apical sodium-dependent bile acid transporter inhibitor (GSK2330672) for treatment of type 2 diabetes.

  2013cited by this paper
• Bile acid metabolism and signaling.

  2013cited by this paper
• Targeted profiling of circulating and hepatic bile acids in human, mouse, and rat using a UPLC-MRM-MS-validated method[S]

  2012cited by this paper
• Bile salts of vertebrates: structural variation and possible evolutionary significance[S]

  2010cited by this paper
• Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts.

  2009cited by this paper
• Bile-acid-induced cell injury and protection.

  2009cited by this paper
• Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice.

  2006cited by this paper
• The heteromeric organic solute transporter alpha-beta, Ostalpha-Ostbeta, is an ileal basolateral bile acid transporter.

  2005cited by this paper
• Feeding natural hydrophilic bile acids inhibits intestinal cholesterol absorption: studies in the gallstone-susceptible mouse.

  2003cited by this paper
• 1-[4-[4[(4R,5R)-3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]butyl]-4-aza-1-azoniabicyclo[2.2.2]octane Methanesulfonate (SC-435), an Ileal Apical Sodium-Codependent Bile Acid Transporter Inhibitor Alters Hepatic Cholesterol Metabolism and Lowers

  2002cited by this paper
• Control of Cholesterol Turnover in the Mouse*

  2002cited by this paper
• Bile acid concentrations in human and rat liver tissue and in hepatocyte nuclei.

  1997cited by this paper
• Hepatic levels of bile acids in end-stage chronic cholestatic liver disease.

  1996cited by this paper
• Influence of Hydroxylation and Conjugation of Bile Salts on Their Membrane‐Damaging Properties‐Studies on Isolated Hepatocytes and Lipid Membrane Vesicles

  1984cited by this paper
• Comparative effects of cholic, chenodeoxycholic, and ursodeoxycholic acids on micellar solubilization and intestinal absorption of cholesterol.

  1981cited by this paper

• Profiling Bile Acids in the Stools of Humans and Animal Models of Cystic Fibrosis

  2025cites this paper
• Benefits and challenges to therapeutic targeting of bile acid circulation in cholestatic liver disease

  2025influential citation
• Profiling bile acids in the stools of humans and animal models of cystic fibrosis

  2025cites this paper